| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Gomisin O targets multiple pathways involved in oxidative stress, inflammation, and cell protection. Its hepatoprotective activity is attributed to its ability to reduce oxidative stress and protect liver cells from injury. Its anti-inflammatory activity involves the inhibition of pro-inflammatory mediators. Its neuroprotective effects may involve the modulation of oxidative stress and inflammation in the central nervous system. The compound's antioxidant activity involves scavenging free radicals and enhancing cellular antioxidant defenses.
|
|---|---|
| ln Vitro |
In vitro studies demonstrate that Gomisin O exhibits potent hepatoprotective, antioxidant, anti-inflammatory, and neuroprotective activities. The compound protects liver cells from chemical and oxidative injury. It reduces inflammation by inhibiting the production of pro-inflammatory cytokines. Its neuroprotective effects have been demonstrated in models of oxidative stress and neurodegeneration. The compound's antioxidant activity is assessed using DPPH, ABTS, or ORAC assays, where it scavenges free radicals.
|
| ln Vivo |
In vivo activity of Gomisin O has been evaluated in animal models. The compound has been shown to protect liver cells from chemical and oxidative injury in vivo. Its anti-inflammatory effects have been demonstrated in models of inflammation. Its neuroprotective effects have been studied in models of stress and cognitive impairment. However, detailed in vivo efficacy data are limited. The compound is primarily used as a research tool for studying hepatoprotection and neuroprotection.
|
| Enzyme Assay |
In vitro assays for Gomisin O involve measuring its antioxidant, anti-inflammatory, and hepatoprotective activities. Antioxidant activity is assessed using DPPH, ABTS, or ORAC assays. Anti-inflammatory activity is evaluated in cell-based assays by measuring the inhibition of pro-inflammatory cytokine production in stimulated macrophages. Hepatoprotective activity is assessed in liver cell lines (e.g., HepG2) treated with the compound and exposed to chemical or oxidative injury, with cell viability measured by MTT or similar assays.
|
| Cell Assay |
Cellular assays for Gomisin O are conducted to evaluate its hepatoprotective, anti-inflammatory, and neuroprotective effects. Liver cells (e.g., HepG2) are treated with the compound and exposed to chemical or oxidative injury (e.g., CCl4, H2O2). Cell viability is assessed using MTT or similar assays. Inflammatory cytokine production is measured in stimulated immune cells using ELISA. Neuroprotective effects are assessed in neuronal cells exposed to oxidative stress or other insults, with cell viability measured by MTT.
|
| Animal Protocol |
In vivo animal studies with Gomisin O are conducted in models of liver injury, inflammation, and cognitive impairment. Animals are treated with the compound via oral or intraperitoneal administration at various doses. Liver injury is induced by chemicals such as CCl4 or by oxidative stress. Liver function is assessed by measuring serum ALT, AST, and histopathological examination. Inflammatory markers are measured in serum or tissues. Cognitive function is assessed using behavioral tests.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Gomisin O have not been extensively characterized. The compound has a molecular weight of 416.46 and a molecular formula of C23H2₈O₇. It has a melting point of 145-146.5degC. Detailed PK parameters such as half-life, bioavailability, and volume of distribution are not reported in the available literature. The compound is typically stored at -20degC.
|
| Toxicity/Toxicokinetics |
Toxicological data for Gomisin O are limited. The compound is not intended for human therapeutic use and is supplied for research purposes only. In cell-based assays, the compound is generally well-tolerated at concentrations used for activity studies. The compound is derived from Schisandra chinensis, a plant used in traditional medicine with a generally favorable safety profile. Standard safety precautions should be followed when handling this compound.
|
| Additional Infomation |
Schisandrin O has been reported to exist in Schisandra chinensis, Schisandra lilycosum, and other organisms with relevant data. See also: Schisandra chinensis fruit (partial).
Gomisin O is a dibenzocyclooctadiene lignan from Schisandra chinensis with hepatoprotective, antioxidant, anti-inflammatory, and neuroprotective activities. It protects liver cells from injury, reduces inflammation, and improves cognitive resilience. The compound is not an FDA-approved drug and has no clinical indications. It is available in high purity and is typically stored at -20degC. |
| Molecular Formula |
C23H28O7
|
|---|---|
| Molecular Weight |
416.4642
|
| Exact Mass |
416.183
|
| CAS # |
72960-22-6
|
| PubChem CID |
5317808
|
| Appearance |
Off-white to light yellow solid
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
575.6±50.0 °C at 760 mmHg
|
| Flash Point |
301.9±30.1 °C
|
| Vapour Pressure |
0.0±1.7 mmHg at 25°C
|
| Index of Refraction |
1.558
|
| LogP |
4.81
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
30
|
| Complexity |
574
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
O([H])[C@@]1([H])C2=C([H])C(=C(C(=C2C2=C(C3=C(C([H])=C2C([H])([H])[C@]([H])(C([H])([H])[H])[C@]1([H])C([H])([H])[H])OC([H])([H])O3)OC([H])([H])[H])OC([H])([H])[H])OC([H])([H])[H])OC([H])([H])[H]
|
| InChi Key |
GWDFJIBHVSYXQL-SYTFOFBDSA-N
|
| InChi Code |
InChI=1S/C23H28O7/c1-11-7-13-8-16-21(30-10-29-16)22(27-5)17(13)18-14(19(24)12(11)2)9-15(25-3)20(26-4)23(18)28-6/h8-9,11-12,19,24H,7,10H2,1-6H3/t11-,12-,19+/m0/s1
|
| Chemical Name |
(8R,9S,10S)-3,4,5,19-tetramethoxy-9,10-dimethyl-15,17-dioxatetracyclo[10.7.0.02,7.014,18]nonadeca-1(19),2,4,6,12,14(18)-hexaen-8-ol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4012 mL | 12.0060 mL | 24.0119 mL | |
| 5 mM | 0.4802 mL | 2.4012 mL | 4.8024 mL | |
| 10 mM | 0.2401 mL | 1.2006 mL | 2.4012 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
